DRP Journal

Discover Research Profit

Finance 

Asep Medical Holdings Inc (OTCMKTS:SEPSF) Stock Soars: Here is Why

Ian Leigh , , , ,

Asep Medical Holdings Inc (OTCMKTS:SEPSF) announced the ground-breaking use of artificial intelligence for identifying infections at higher risk of severe sepsis. Developed by Hancock Lab, under the guidance of Dr. Robert E.W. Hancock, Killam Professor at the University of British Columbia, it assesses dysfunctional immune responses for identifying sets of genes to know if a patient will acquire severe sepsis.

Trading Data

On Friday, SEPSF stock ended flat at $0.4000with 15K shares, compared to its average volume 0 shares. The stock moved within a range of $0.4000 – 0.4000 after opening trade at $0.4000.

Asep Inc. Announces Ground-breaking A.I. Technology for Rapid Identification of Severe Sepsis and Improved Superbug Therapies

Dr. Hancock, Chair and CEO of Asep Inc said that the company has utilised AI for obtaining practical outcomes in high unmet medical needs. Hancock added that Sepsis is a severe disease-causing one in five deaths globally. He further said that harnessing the power of AI is enabling the team to assess whether a patient, including someone having covid will acquire sepsis.

Dr. Hancock also said that the SepsetER test has worked well, and the bioinformatics scientists have applied AI for reporting outcomes. The CEO confirmed that the company is preparing for a confirmatory clinical trial at St. Paul’s Hospital inVancouver, BC.

The clinical trial comes before a larger study aimed at demonstrating sepsis diagnostic technology’s performance and compares it to the available sepsis tests.

Asep Inc is anticipating that the 510(k)-application process would finish in quarter one of 2024 and the test will be available to hospitals later.

Ian Leigh

Ian Leigh is a specialist in analyzing stocks, SEC and OTC filings, and financials of public and privately-held companies. He has played a significant role in M&A activity, consulting with publicly-held firms on acquisitions and divestitures. He also consults on valuations and branding. He lectures at major universities and teaches at specialty financial schools.